For research use only. Not for use in humans.

Acasunlimab (Anti-4-1BB & PD-L1)

Synonyms: GEN 1046

Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa

Acasunlimab (Anti-4-1BB & PD-L1)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet

Specificity

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 1
BMS-1001 0
BMS-1166 8
PD-1/PD-L1 Inhibitor 3 13
BMS-1 13
BMS202 26
CA-170 (AUPM-170) 0
SR 0987 1 IL17,RORγt
Spartalizumab (anti-PD-1) 3
Camrelizumab (anti-PD-1) 2
AUNP-12 3
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Acasunlimab is a recombinant Fc-silenced IgG1 bispecific antibody targeting PD-L1 and 4-1BB, with checkpoint inhibitory, immunostimulating, and antineoplastic activities. It enhances antitumor immune response by enabling conditional 4-1BB activation strictly dependent on PD-L1 binding. M.W 144.3 kDa

Product Details

CAS No. 2253937-12-9
Source CHO
Storage
(From the date of receipt)
-80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.